You are here: Home » PTI Stories » National » News
Business Standard

Human cells with 'built-in circuit' to help stop cancer growth

Press Trust of India  |  London 

Scientists have engineered cells with a 'built-in genetic circuit' which produces a molecule that inhibits the ability of tumours to survive and grow in their low oxygen environment.

The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of cells.



This in the cells being unable to survive in the low oxygen, low nutrient tumour micro-environment.

As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This in cells needing to adapt to low oxygen environment.

To enable them to survive and grow in the low-oxygen or 'hypoxic' environments, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1).

HIF-1 senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new blood vessels.

It is thought that tumours primarily hijack the function of this protein (HIF-1) to survival and grow.

"In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment," said Ali Tavassoli, professor at the University of Southampton in the UK.

"We've been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected," said Tavassoli.

"In a wider sense, we have given these engineered cells the ability to fight back - to stop a key protein from functioning in cells," he said.

"This opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer," said Tavassoli.

The genetic circuit is incorporated onto the chromosome of a human cell line, which encodes the protein machinery needed for the production of their cyclic peptide HIF-1 inhibitor.

The production of the HIF-1 inhibitor occurs in response to hypoxia in these cells. The research team demonstrated that even when produced directly in cells, this molecule still prevents the HIF-1 signalling and the associated adaptation to hypoxia in these cells.

"The main application for this work is that it eliminates the need for the synthesis of our inhibitor, so that biologists conducting research into HIF function can easily access our molecule and hopefully discover more about the role of HIF-1 in cancer," said Tavassoli.

The study was published in the journal ACS Synthetic Biology.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Human cells with 'built-in circuit' to help stop cancer growth

Scientists have engineered cells with a 'built-in genetic circuit' which produces a molecule that inhibits the ability of tumours to survive and grow in their low oxygen environment. The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of cancer cells. This results in the cancer cells being unable to survive in the low oxygen, low nutrient tumour micro-environment. As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This results in cancer cells needing to adapt to low oxygen environment. To enable them to survive and grow in the low-oxygen or 'hypoxic' environments, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1). HIF-1 senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the ... Scientists have engineered cells with a 'built-in genetic circuit' which produces a molecule that inhibits the ability of tumours to survive and grow in their low oxygen environment.

The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of cells.

This in the cells being unable to survive in the low oxygen, low nutrient tumour micro-environment.

As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This in cells needing to adapt to low oxygen environment.

To enable them to survive and grow in the low-oxygen or 'hypoxic' environments, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1).

HIF-1 senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new blood vessels.

It is thought that tumours primarily hijack the function of this protein (HIF-1) to survival and grow.

"In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment," said Ali Tavassoli, professor at the University of Southampton in the UK.

"We've been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected," said Tavassoli.

"In a wider sense, we have given these engineered cells the ability to fight back - to stop a key protein from functioning in cells," he said.

"This opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer," said Tavassoli.

The genetic circuit is incorporated onto the chromosome of a human cell line, which encodes the protein machinery needed for the production of their cyclic peptide HIF-1 inhibitor.

The production of the HIF-1 inhibitor occurs in response to hypoxia in these cells. The research team demonstrated that even when produced directly in cells, this molecule still prevents the HIF-1 signalling and the associated adaptation to hypoxia in these cells.

"The main application for this work is that it eliminates the need for the synthesis of our inhibitor, so that biologists conducting research into HIF function can easily access our molecule and hopefully discover more about the role of HIF-1 in cancer," said Tavassoli.

The study was published in the journal ACS Synthetic Biology.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Human cells with 'built-in circuit' to help stop cancer growth

Scientists have engineered cells with a 'built-in genetic circuit' which produces a molecule that inhibits the ability of tumours to survive and grow in their low oxygen environment.

The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of cells.

This in the cells being unable to survive in the low oxygen, low nutrient tumour micro-environment.

As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This in cells needing to adapt to low oxygen environment.

To enable them to survive and grow in the low-oxygen or 'hypoxic' environments, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1).

HIF-1 senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new blood vessels.

It is thought that tumours primarily hijack the function of this protein (HIF-1) to survival and grow.

"In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment," said Ali Tavassoli, professor at the University of Southampton in the UK.

"We've been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected," said Tavassoli.

"In a wider sense, we have given these engineered cells the ability to fight back - to stop a key protein from functioning in cells," he said.

"This opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer," said Tavassoli.

The genetic circuit is incorporated onto the chromosome of a human cell line, which encodes the protein machinery needed for the production of their cyclic peptide HIF-1 inhibitor.

The production of the HIF-1 inhibitor occurs in response to hypoxia in these cells. The research team demonstrated that even when produced directly in cells, this molecule still prevents the HIF-1 signalling and the associated adaptation to hypoxia in these cells.

"The main application for this work is that it eliminates the need for the synthesis of our inhibitor, so that biologists conducting research into HIF function can easily access our molecule and hopefully discover more about the role of HIF-1 in cancer," said Tavassoli.

The study was published in the journal ACS Synthetic Biology.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard